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The injection of either viable B16 melanoma cells, 
killed B16 cells, or B16 cell products increased the inci-
dence of melanomas in C57Bl/6J mice inoculated with a 
threshold dose of B16 cells. In all cases the effect was 
seen whether the facilitating injection was at a site dis-
tant from the challenge inoculum or at the same site. 
Facilitation was seen with B16 cells and products both 
from in vivo tumors and from tissue culture. However, 
cells detached from tissue culture flasks with trypsin no 
longer had facilitating activity. Facilitating activity was 
found in concentrated culture s upernatants centrifuged 
at 100,000 x g for 1.5 hr and dialyzed. No activity was 
detected in the less than 10,000 mol wt fraction. Facili-
tation was not associated with a change in the time of 
tumor appearance nor with enhanced growth of B16 
cells in culture. 
The growth of a tumor in a host following the injection of 
m alignant cells requires inoculation of a particular minimal 
numbe r of tumor cells. The requirement for a threshold number 
of cells to produce a tumor take is likely due to cer ta in in trinsic 
properties of malignant cells (i.e., tuinorigenicity) and to the 
host's capacity to destroy or suppress smaller numbers of po-
tentially tumorigenic cells. Variations in the tumorigenicity of 
malignant cells may indicate that these cells play an active role 
in assuring thei1· own surviva l in the host, perhaps by synthe-
s izing substances to oppose t he host defense system. Under-
standing the cause and mechanism of the thresho ld response 
would have great bearing on the question of tumor initiation. 
We have approached the problem of t he threshold dose using 
as a basic concept the cl inical observation that the primary 
t umor mass itself seems to enhance the appearance of meta-
static lesions. Tumor products that stimulate tumor initiation 
or interfere with immune mechanisms have been found in other 
experimental systems. Various tumor products a re reported to 
inhibi t Listeria resistance [1], macrophage chemotaxis [2- 5], in 
vitro ce llular cytotoxicity [6), lymphocyte mitogen response [7-
9), and in vivo plaque forming cell response to sheep red blood 
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cells [10-12). Tumor products can also accelerate in vivo t umor 
growth or incr ease the incidence of t umor takes [2,6,9,13,14). 
Thus, there is considerable evidence t hat tumors produce fac-
tors capable of inhibi t ing the defense mechanisms of the host 
and facilitating tumor growth. 
Using the murine B16 melanoma system in syngeneic C57Bl/ 
6J mice, it was found that viable and killed B16 cells from 
tumors, tissue culture, and tissue culture supernatants all in-
creased the percentage of mice developing tumors following the 
injection of B16 cells. This effect was seen when the material 
was injected at a site distant from the challenge inoculum, as 
well as when it was administered at t he same site as the 
challenge. We have termed this effect "facili tation" to distin-
guish it fTom other phenomena that enhance tumor takes and/ 
or tumor growth . 
MATERIALS AND METHODS 
Mice 
Virgin fema le C57BI/6J mice greater than 10 weeks of age were used 
for a ll experiments . The mice were obta ined from Jackson Laboratories, 
Bar Hm·bor, Maine, or raiser! in this Department from Jackson stock. 
B/6 Melanoma 
Bl6 melanoma arose as a rare spontaneous event in a C57B I/ 6J 
mouse at Jackson Laboratory. The B 16 cells used in these experiments 
were adapted to tissue cul ture and cloned in our laboratory fro m a 
tumor-bearing C57BI/6J mouse obtained fro m Dr. J . C. Brystryn (New 
York University Medical Center). Our laboratory's line is deeply pig-
mented whether growing in vivo or in vitro. In our experience a B16 
tumor take never regresses and is a lways letha l. B 16 cells were main-
ta ined in monolayer cul tw·es using RPMI 1640 medium (G IB CO, Grand 
Isla nd, NY) supplemented with 5% fetal calf serum (FCS) + (Microbio-
logical Associates, Bethesda, Md.) , streptomycin 100 J.Lg/ rnl, a nd peni-
cillin 100 U/ ml. Cells were passaged approximate ly twice a week using 
0.5% trypsin in PBS to detach cells from cul ture fl asks. 
Both tissue culture cells a nd cells from B16 tumors were killed by 
freezing a nd thawing. Tissue cul ture ce lls were detached from mono-
layers with phosphate buffered saline (PBS), pH 7.2, containing either 
2 mM EDTA or 0.5% t ry psin, whereas ce lls were obtained from excised 
tumors (approximately 1 em in diameter) by gently teasing the t issue 
in to PBS. The supensions were dilu ted to 5 X 107 cells/ ml PBS and 
subjected to 3 cycles of freezing in liquid nitrogen by slow thawing at 
room temperature. Cell viabili ty was assayed by t rypan blue dye 
exclusion. There were no viable ce ll by this method . The suspensions 
were stored in a liquot;s in liquid ni trogen. 
B /6 Culture Supem alanls 
The fo llowing procedu re was utilized to obtain supernata nt fluids of 
Bl6 cells as fi·ee as possible from extraneous serum protein . Cultures 
in complete medium were grown to confluency in 150 em" disposable 
fl asks (Corning, Corning, New York). Each flask then conta ined ap-
proximately 5.0 x 107 viable ce lls. The medium was decanted and the 
mono layers washed twice with PBS. Ten ml of serum-free medium was 
added to each flask and the flask were incubated for 5 hr at 37°C. T he 
fluids were hru·vested and complete med ium was then added. After 
overnight incubation in co mplete medium the procedure was repeated . 
A tota l of 3 ha rvests/ fl ask was obtained in this fashion. The pooled 
supernatants were then concentrated 20-fold on an Amicon PM 10 
membra ne (Amicon Corp. , Lexington, MA) which holds back molecules 
greater than 10,000 mol. wt. T he concentra tion was centri fuged a t, 
100,000 Xg for 1.5 hr, exhaustive ly dia lyzed aga inst PBS, and sterilized 
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by fil t ration through a .45 J.LM millipore fi ller (Mi llipore Corp. , Bedford , 
MA). Protein concentration was determined by the method of Lowry 
et al [ 15]. 
B /6 Tumors 
All injections of the cha llenge tumor ce ll inocula were of cells from 
tissue culture in a volume of 0.2 ml of complete medium and, unless 
otherwise noted, were subcutaneous into the righ t fl a nk. The number 
of ce lls used in each experiment appears in the legend for each table. 
The numbers are fo r viable cells with viability counts always in excess 
of 95% as determined by trypan blue exclusion. Other materia ls were 
inoculated either into the same site or the contralate ral flank. The 
injection of other materials occurred at the same Lime as the injection 
of viable cells. S ites were inspected and palpated twice a week for 12 
weeks. Differences between groups were a nalywd statistically by the 
Chi-square test. 
RESULTS 
E ffect of a Second Injection of B16 Cells on Tumor Incidence 
It is generally assumed that the determining factor for tumor 
take in an individual experimenta l animal is the number of cells 
inocula ted at a given site, i. e. the threshold dose must be 
exceeded. However, it is also possible that the threshold dose 
need not be restricted to one site, rather, the threshold is 
determined by the total number of tumor cells or tumor bmden 
of the animal rega1·dl ess of the number of sites in which tumor 
cells are distributed. Several experiments were performed to 
clarify this point. 
In these experiments control animals were injected with 8 x 
10'' cells in one flank while experimental mice received 8 X 104 
cells in both fl anks (total 1.6 X 10'' ceiJs/mouse). When cells 
were injected into one flank, tumors a rose in 50%, 11%, and 40% 
of animals in 3 sepa rate experiments (Table I). However, when 
the same number of cells was injected into both fl anks, 100%, 
40%, and 1QO% of mice respectively, developed tumors. There 
was also an increase. in the percentage of injection sites at which 
tumors developed. This suggests that the effective threshold for 
the mouse is the total tumor burden rather than the number of 
tumor cells in a given site. 
E ffect of Frozen-Thawed Tumor-Derived Cells on BJ6 
Tumor Incidence 
In order to determine whether killed cells from B16 tumors 
affected tumor takes, frozen-thawed cells were prepared as 
described and injected into either the same or the contralateral 
flank as a suboptimal dose of viable Bl6 cells. The data in 
Table II are from a series of experiments, each using a different 
batch of frozen-thawed cells. It can be seen from the pooled 
results that whether the dead cells were injected into the same 
(A) or the opposite (B) flank, t here wa::; a significant increase in 
tumor take over that in animals injected with the viable cells 
only. In no case did tumors arise at the site of injection of killed 
cells. 
TABLE l. Effect of a second injection. of B/6 tu.m.or cells on tunwr 
incidence 
Tumor in cid ence (g roup size) 
A B c 
One site/ mouse: 
Percent mice with tu- 50% (20) 11 % (9) 40% (10) 
mors 
Two sites/ mouse: 
Percen t mice with tu- JOO% (6) 40% (10) JOO% (10) 
mors 
Percent sites with tu- 83% (12) 30% (20) · 70% (20) 
mors 
C57BI/6J female mice were injected with 8 X 10'' B l6 cells subcuta-
neously in either the right fl ank a lone, or in both the right and left 
fl ank (total 1.6 X 10''/mouse). The letters indicate th ree independent 
experiments. 
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TABLE II. Effect of frozen -thawed Bl6 cells derived from tumors on 
B 16 tumor incidence 
A. Frozen-thawed a nd viable Bl6 cells in same site 
Percent mice with tumors (group size) 
Control" 50 (20) 
Experimenta l 93 (15) 1' 
B. Frozen-thawed a nd viable BW cells in distant sites: 
Cont rol -PBS" 
Experimental 








71 (35) '' 
"C57BI/6J mice were injected subcutaneously with 8 X 10'' viable 
Bl6 cells and 1.07 frozen-thawep Bl6 cells in either the same or opposite 
th igh. Control animals received 8 X 10'' viable B IG cells. Anima l in pa r t 
B a lso rece ived a n injection of PBS in t he opposite thigh. Each pail' of 
numbers represents an independent experiment with a different prep-














" p < 0.05. 
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Effect of Viable and D ead B16 Cells on Bl6 Tumor Ini tiation. 
Similar data is presented in the Figure to depict the con-
sistency of the frequency with which facili tated mice grow 
tumors. Regardless whether live or dead B16 cells in either the 
same or a separate site were used to facilitate tumor initiation 
the curves for the frequency of initiation are nearly overlapping: 
These curves a1·e distinctly different from that of control ani-
mals. 
E ffect of Frozen -Thawed Cultured B16 Cells on B16 Tumor 
Tahe 
Since tumors excised from animals contain a number of cell 
types in addition to the melanoma cells, it was important to 
establish whether a homogeneous population of Bl6 cells from 
tissue cultures also enhanced tumor takes. B16 cells in mono-
layer cultuTes at confluence were detached fi ·om the fl asks by 
2 min incubation with either 2 mM EDTA or 0.5% trypsin in 
PBS. After the 2 min period the trypsin was inactivated with 
5% FCS in PBS. The cells were harvested by centrifugation and 
frozen and thawed as described. 
As shown in Table III the injection of B16 cells harvested 
with EDTA significantly (P < 0.05) increased the proportion of 
mice developing tumors. No tumors arose at the site of injection 
of frozen-thawed cells. In contrast, frozen -thawed Bl6 cells 
harvested with trypsin did not enhance tumor take nor did the 
trypsin-containing supernatant have any effect. Many addi-
tional experiments over a broad range of doses have confirmed 
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that B16 cells harvested with tryp in , unlike those obta ined 
with EDTA, do not facilitate tumor ta ke. 
The Effect of Concentrated BI6 Culture Supernatants on B16 
Tumor Tahe 
B16 culture superna tant was tested for the ability to facilitate 
t umor take. Mice were injected subcutaneously in the left flank 
with either 0.3 ml or 0.7 ml of 20-fo ld concentrated Bl6 culture 
supernatant prepared as previously described. Control mice 
were injected wi th 0.7 ml of PBS in the left flank. Three 
independent experiments were performed using different cul-
ture supernatant preparations that had protein concentrations 
of 660 J.tg/ ml, 670 J.tg/ ml, and 1.0 mg/ ml. As shown in Table IV 
all three prepa1·ations sign ificantly increased the incidence of 
tumor takes in the contralatera l side when 0. 7 ml was injected. 
Fetal calf serum, a contaminant in the Bl6 culture superna-
tant, did not a lter tumor development when tested over a wide 
dose range. As noted previously, the active culture supernatants 
h ad been concentrated by a membrane filter which held back 
material greater than 10,000 mol. wt., centrifuged at 100,000 
xg for 1.5 hr, and dialyzed. Material that passed through t he 
10,000 mol. wt. exclusion filter was concentrated 40-fold on an 
Amicon UM2 1,000 mol. wt. exclusion filter, and tested for 
tumor facilitating activity. This material was found to be inac-
tive when tested at doses of 0.25 ml, 0.5 ml, or 1.0 ml per mouse. 
It was possible that the cultme superna tant fluids exerted 
their effect by increasing the growth rate ofB16 cells. However, 
in vitro studies in which various amounts of concentrated 
supernatants were added to cu ltures of B16 cells revealed that 
the supernatants not only did not enhance the in vitm growth 
rate of Bl6 cells but were toxic at concent rations as low as 25 
TABLE 111. Effect of fro zen -thawed cultured 816 ce/li; on B16 tumor 
in cidence 
Percentage of mice with t.umo fs 
(group size) 
Control" 
EDTA collected frozen-thawed 
Bl6 cells: 
5 x 10,; cells 
106 cells 
T rypsin collected frozen-thawed 
Bl6 cells: 
5 X 10,; cells 
10'; cells 







5 X lOH cell equivalents 0 (10) 
10'; cell eq uivalents 10 (10) 
Inactivated trypsin control 11 (9) 
B T otal 
27 (15) 14 (35) 
50 (10) 47 (19) 1' 
"C57BI/6J female mice were injected with 7.5 X 10'' viable Bl6 cell 
s.c. in the right nank. Additional materials were injected s.c. in the left 
flank. No tumors arose at the site of injection of frozen-thawed BIG 
cells. Trypsin was inar.;tivated with fetal bovine sera. 
"p < 0.05 by Chi-sq uare. 
TABLE IV . Effect of concentrated B 16 culture t;upemata.nt on 131 6 
tumor incidence" 
A 
PBS 16% (30) 
Bl6 cul ture su-
pernatant: 
Percentage of mice wi th lumors 
(group siw) 
B c 
16% (30) 37% (30) 
Tow I 
23% (90) 
0.3 ml 30% (10) 20% (10) LO% (10) 20% (30) 
0.7 ml 50% (8) 50% (10) 70% (tO) 57% (28)" 
"All mice received 7.5 x 10'' BIG cells s.c. in the right nank. Addi-
t ional materials were injected in the left fl ank. The protein content of 
the three B16 cul ture supernatant preparations was 0.66 mg/ ml, 0.67 
mg/ ml, and l.O mg/ml respectively. 
"p < 0.01 as determined by Chi-square. 
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200 l'g/ ml" 
100 l'g/ ml 
50 l'g/ ml 
251tg/ml 
10 ftg/ ml 
2 pg/ ml 
B I 6 Cells per fl ask on Day 5 
1% FCS 
2.07 X 10'; ± 0. 17" 
I. II X 10'; ± 0. 14 
l.(i9 X 10'; ± 0.07 
1.92 X 10'; ± 0.10 
5% FCS 
:J.43X 10';± 0. 14 
2.34 X 101; ± 0.35 
2.84 X I 0" ± 0.36 
3.28 X 10'1 ± 0. 15 
3.28 X 10'; ± 0. 17 
3.2fl X 10'; ± 0.27 
5 X 10'' B 16 ce lls were udded to each 25 em' fl nsk wit.h 10 ml of supplement ed 
HPMI 1640 medium. T he medium was changed the fo ll owing day a nd appropriate 
amounts of 20- fold concentrated BIG culture supernata nt was added t.o t.he fl asks. 
On day 5 th e Bl 6 cells were detached with trypsin a nd coun ted. 
"± SEM (N = 4 fl asks). 
1
' Prote in content. as determin ed by th e method of Lowry et. a l [1 5]. 
J.tg protein/ ml (Table V). Moreover, t he repeated observation 
(unpublished) that the mean time of tumor appearance and 
rate of growth remained unchanged from that of the controls, 
irrespective of the source of facilitati ng material injected, also 
suggest that TFF does not act by increasing the rate of cell 
division. 
DISCUSSION 
The injection of viable Bl6 cells, killed B16 tumor or t issue 
culture cells, or B16 tissue culture supernatant fluids all en-
hanced the incidence of B16 tumor development from a sub-
optimal inoculum. We h ave termed this phenomenon "facilita-
tion ." Facilitation was evident when viab le cells were inoculated 
into the contralatera l flank. Simila rly, killed cells and culture 
supernatan t fluids facilitated tumor development whether in-
jected together with or at a site distant from the challenge 
inoculum. This is in contrast to the fi ndings of R evesz that 
viable mouse mammary car cinoma cells facilitated tumor 
growth whereas killed cells did not (16]. 
Although the nature, specificity, and mechanism of action of 
the facilitating factor(s) remain to be ascertained, the current 
stud ies provide preliminary information on these questions. 
Firstly, it was found that cul tured Bl6 cells detached with 
trypsin and disrupted by freeze-thawing did not facilitate 
whereas those detached with EDTA and disrupted did . Since 
cells detached from flasks with t rypsin are viable as judged by 
trypan blue dye exclusion, it is possible that trypsin destroyed 
the tumor facilitating activity of intact cells. In addi tion, sig-
nificant quantities of this facili tating material are no t present 
within the B16 cells since prior to injection into mice the trypsin 
treated cells were disrupted by freeze-thawing, presumably 
releasing any internal tumor fa cilitat ing factor. It is thus likely 
that the activity is a cell surface component that is a protein , or 
at least contains a vital trypsin-sensit ive protein domain. 
It was found that facilitat ion is a systemic process, bu t it is 
not clear whether t he facili tating factor acted directly upon the 
cha ll enge dose or if the action was mediated by a lterations in 
host physiology. However, it is unlikely that the facili tating 
factor acted directly upon the Bl6 cells because facilitating 
culture supernatants did not stimulate Bl6 cell growth in vitro, 
a nd indeed they were toxic. Moreover, the mean time of tumor 
a ppear ance and tumor growth rates were unchanged. 
If facilitating fa ctor operates through a lterations in the host 
response to the inoculum, there a1·e a number of po s ibili t ies 
including inhibi tio n of the inflammatory and/ or immunological 
response to the tumor challenge. T he factor is clearly different 
from the facili tating material described by Synderman and his 
associates [14,1 7]. While their material is obtained from tumor 
homogenates a nd presumably exerts its facili tating activi ty by 
inhibit ing macrophage chemotactic response, the active product 
is dialyzab le, whereas facilitating Bl6 melanoma cell p roducts 
are nondialyzable. There ru·e addi tional reports of tumor-de-
rived materials that alter tumor growth or . development 
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[2,6,9,13], but most of t hese materials are also described as 
dia lyzable. 
It seems unlikely that facilitation of Bl6 melanomas is due to 
a diminished immune response because the tumor is poorly 
immunogenic. Characterization and definition of the mode of 
action of th e facilitating factor are currently in progress and 
may provide information applicable to a n understanding of the 
development of tumor foci, part icularly metastatic foci. 
We are ve ry gratefu l to Dr. Stephen I. M orse for cri t ica lly reviewing 
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